Online inquiry

IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14982MR)

This product GTTS-WQ14982MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Diseases or disorders including airway inflammation research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14982MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9211MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ8458MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ1846MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ14598MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SAR-650984
GTTS-WQ14168MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ1664MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACT-017
GTTS-WQ15998MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ11340MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-551
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW